华昊中天医药-B(02563)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02563 华昊中天医药-B

未开盘 10-22 15:49:03

3.900

+0.100

+2.63%

最高3.900	最低3.600	成交量3.52万
今开3.600	昨收3.800	日振幅7.89%
总市值15.21亿	流通市值15.21亿	总股本3.90亿
成交额13.42万	换手率0.01%	流通股本3.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02563","market":"HK","secType":"STK","nameCN":"华昊中天医药-B","latestPrice":3.9,"timestamp":1792655343451,"preClose":3.8,"halted":0,"volume":35200,"delay":0,"changeRate":0.026315789473684237,"floatShares":390000000,"shares":390000000,"eps":-0.36,"marketStatus":"未开盘","change":0.1,"latestTime":"10-22 15:49:03","open":3.6,"high":3.9,"low":3.6,"amount":134220,"amplitude":0.078947,"askPrice":3.785,"askSize":400,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":0,"adr":0,"listingDate":1730304000000,"exchange":"SEHK","adjPreClose":3.8,"openAndCloseTimeList":[[1792632600000,1792641600000],[1792645200000,1792656000000]],"volumeRatio":2.784810148614004,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02563","defaultTab":"news","newsList":[{"id":"2676645086","title":"华昊中天医药-B(02563)：优替德隆胶囊治疗HER2阴性晚期乳腺癌III期临床首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2676645086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676645086?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:07","pubTimestamp":1792490877,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B 发布公告，本公司核心管线优替德隆胶囊治疗人表皮生长因子受体2阴性晚期乳腺癌III期临床研究成功实现首例患者给药，标志着全球首个口服固体微管稳定剂关键性注册临床正式启动。研究为一项优替德隆胶囊与已上市的优替德隆注射液分别联合卡培他滨在既往接受过紫杉类或蒽环类药物治疗的HER2阴性晚期乳癌患者中随机、对照的、针对无进展生存期的非劣效桥接试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","BK1515","09939","02563","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184190328","title":"华昊中天医药-B（02563）完成口服优替德隆治疗HER2阴性晚期乳腺癌III期临床首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1184190328","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184190328?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:05","pubTimestamp":1792490730,"startTime":"0","endTime":"0","summary":"2026年10月20日，北京华昊中天生物医药股份有限公司发布自愿公告称，其核心管线产品优替德隆胶囊治疗HER2阴性晚期乳腺癌的III期临床研究已完成首例患者给药，标志着全球首个口服固体微管稳定剂的关键注册试验正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157830362","title":"港股创新药概念股集体走低，华昊中天医药-B跌超11%、金斯瑞生物科技跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157830362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157830362?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:38","pubTimestamp":1791855517,"startTime":"0","endTime":"0","summary":"10月13日，港股创新药概念股集体走低，$华昊中天医药-B(02563)$跌超11%，$金斯瑞生物科技(01548)$跌超10%，$药明合联(02268)$、$晶泰控股(02228)$跌超4%，$药明生物(02269)$、$歌礼制药-B(01672)$跌超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422952.EUR","LU1880383366.USD","LU0823426308.USD","BK1617","LU0516423091.SGD","LU0516422366.SGD","LU0244354667.USD","LU2778985437.USD","LU0979878070.USD","HK0000320223.HKD","KCAI","LU1688375341.USD","02563","LU0516423174.USD","BK4588","LU0708995153.HKD","BK1141","VXUS","06978","KURE","LU0320764243.SGD","LU0327786744.USD","LU0417516738.SGD","LU2476274720.SGD","BK1515","IE00B0JY6N72.USD","LU0128522744.USD","LU0828237510.HKD","LU0516422440.USD","LNGR","LU0456846285.SGD","SG9999002463.SGD","02268","LU2488822045.USD","LU0211977185.USD","LU0359201612.USD","LU0540923850.HKD","LU0588546209.SGD","LU1242518857.USD","LU0359202008.SGD","LU1794554557.SGD","02269","HK0000306685.HKD","BK1589","LU0140636845.USD","LU0320764599.SGD","SG9999014674.SGD","LU0043850808.USD","LU0307460666.USD","LU0819121731.USD","01548","LU3063872942.SGD","IBBQ","LU0456827905.SGD","LU0572944931.SGD","LU0417516902.SGD","LU1831875114.USD","LU0561508036.HKD","BK1576","LU0051755006.USD","LU0823426480.USD","LU2476274308.USD","09939","LU0463099449.HKD","LU0128526141.USD","01477","SG9999002562.SGD","LU0708995583.HKD","BK4585","MEDX","02228","LU0029874905.USD","LU0348827113.USD","LU1242518931.SGD","BK1583","HK0000306701.USD","LU0029874061.USD","LU0326950275.SGD","LU1188198961.HKD","HK0000320264.USD","LU0348735423.USD","LU2039709279.SGD","LU0634319403.HKD","BK1610","LU0052750758.USD","BK1574","LU0348825331.USD","LU0181495838.USD","LU0039217434.USD","BK1161","01672","LU0856984785.SGD","LU1720050803.USD","LU0228659784.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129244917","title":"华昊中天医药-B更新9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1129244917","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129244917?lang=zh_cn&edition=full","pubTime":"2026-10-07 18:21","pubTimestamp":1791368490,"startTime":"0","endTime":"0","summary":"北京华昊中天生物医药股份有限公司于2026年10月7日发布公告，披露了截至2026年9月30日止月份的证券变动月报表。截至2026年9月30日，公司注册股本维持人民币389,588,000元，其中法定/注册股份数目为389,588,000股，面值每股人民币1元。公司无新增发行、购回、注销或库藏股记录，股权结构保持稳定。本次公告由公司秘书陈奕斌签署。公司表示，未来将严格遵守香港联交所相关规则及适用法律法规，持续做好信息披露与公司治理工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154696794","title":"华昊中天医药-B2026年中期营收3,663.50万元，经调整净亏损2,659.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154696794","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154696794?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:02","pubTimestamp":1790067757,"startTime":"0","endTime":"0","summary":"华昊中天医药-B披露的2026年中期财报显示，报告期内营收为3,663.50万元，毛利为3,408.00万元，毛利率继续保持在93%的高位。经调整净亏损2,659.60万元，相较去年同期5,404.10万元的净亏损值，收窄50.80%。成本结构上，2026年中期销售费用为1,590.10万元，同比减少18.60%；管理费用1,824.30万元，同比上升28.20%；研发费用进一步降低至1,905.60万元，同比降幅53.90%。其中，优替德隆注射液带动的商品销售收入达3,191.83万元；独家市场推广权益收入4,716.98万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"华昊中天医药-B2026年中期营收3,663.50万元，经调整净亏损2,659.60万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177411057","title":"华昊中天医药-B更新8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1177411057","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177411057?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:42","pubTimestamp":1788338526,"startTime":"0","endTime":"0","summary":"北京华昊中天生物医药股份有限公司于2026年9月2日发布截至2026年8月31日的证券变动月报表。公司注册资本为人民币389,588,000元，报告期内未发生增减变动。根据公告此前的情况，华昊中天医药-B于2026年3月30日完成147,867,143股非上市股份转为H股，并于2026年7月16日配发25,000,000股新H股，使注册资本由人民币364,588,000元增至人民币389,588,000元，上述变动已反映于此前公告。公司同时确认，截至当月末，其H股满足香港联交所适用的公众持股量等相关上市规则要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119108147","title":"华昊中天医药-B2026年中期营收3,663.50万元，经调整净亏损2,659.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119108147","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119108147?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:52","pubTimestamp":1787755932,"startTime":"0","endTime":"0","summary":"华昊中天医药-B公布2026年中期财报，实现营收3,663.50万元，毛利3,408.00万元，毛利率保持在93%，与上年同期持平。期内经调整净亏损2,659.60万元，较去年同期减少50.8%。研发费用为1,905.60万元，同比下降53.9%，占营收比约52%。公告显示，销售费用为1,590.10万元，同比减少18.6%，主要由于公司对相关支出进行了严格管控。管理费用为1,820.00万元，同比增长28.2%，主要受中介机构服务费增加的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"华昊中天医药-B2026年中期营收3,663.50万元，经调整净亏损2,659.60万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662483227","title":"华昊中天医药-B(02563)公布中期业绩 净亏损2659.6万元 同比收窄50.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662483227","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662483227?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:50","pubTimestamp":1787755809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)公布2026年中期业绩，收入3663.5万元，同比增长147.8%;毛利3408万元，同比增长147.9%;净亏损2659.6万元，同比收窄50.8%;每股亏损0.07元。公告称，营收增长主要由于产品优替德隆注射液市场覆盖持续拓宽，带动产品销量上升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","09939","02563","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660474989","title":"华昊中天医药-B(02563.HK)存仓市值总计8237.50万港元 股东将2500万股股票存入浦银国际证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2660474989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660474989?lang=zh_cn&edition=full","pubTime":"2026-08-20 08:29","pubTimestamp":1787185745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","02563","BK1574","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182507230","title":"华昊中天医药-B(02563)拟于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1182507230","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182507230?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:46","pubTimestamp":1786524360,"startTime":"0","endTime":"0","summary":"华昊中天医药-B(02563)8月12日公告称，公司董事会将于2026年8月26日（星期三）召开会议，讨论以下事项：一是审议并酌情批准截至2026年6月30日止六个月的综合中期业绩及其刊发；二是考虑派付中期股息的建议（如有）；三是处理其他相关事宜。\n公告同时披露，公司现任董事包括执行董事唐莉博士、邱荣国博士、张成先生、关津博士；非执行董事唐进先生、戴雪芬女士；以及独立非执行董事萧恕明先生、叶陈刚博士、朱晓东博士。\n公司提醒投资者关注相关董事会决议及后续公告，以获取截至2026年6月30日止六个月的具体财务数据及潜在分红信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139294037","title":"华昊中天医药-B发布2026年7月股份变动月报表 注册股本增至人民币389,588,000元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139294037","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139294037?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:25","pubTimestamp":1785932740,"startTime":"0","endTime":"0","summary":"北京华昊中天生物医药股份有限公司于2026年8月5日公布了2026年7月股份变动月报表，披露了公司在该报告期内的股本变化情况。公告显示，截至2026年7月31日，公司注册股本由人民币364,588,000元增加至人民币389,588,000元。已发行股份总数由364,588,000股增至389,588,000股，增幅为25,000,000股。本次增发股份为在2026年7月16日根据此前签署的认购协议而配发的25,000,000股新H股。公告显示，目前公司已符合香港联交所《上市规则》的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102735460","title":"华昊中天医药-B7月份股份变动月报：注册股本增至人民币389,588,000","url":"https://stock-news.laohu8.com/highlight/detail?id=1102735460","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102735460?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:35","pubTimestamp":1785832544,"startTime":"0","endTime":"0","summary":"北京华昊中天生物医药股份有限公司于2026年8月4日发布2026年7月31日止月份的股份变动月报。公告显示，截至2026年7月底，公司注册股本由人民币364,588,000元增至人民币389,588,000元，主要因在2026年7月16日根据2026年5月6日签署的认购协议增发并配发了25,000,000股新H股。同时，公司普通股已发行股份数量由之前的364,588,000股增加25,000,000股至389,588,000股，库藏股份数目保持为0。公司表示将继续遵守香港联合交易所有限公司的相关上市规则和法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653274479","title":"Baheal Pharma Group Co., Ltd.增持华昊中天医药-B(02563)2500万股 每股作价4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653274479","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653274479?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:20","pubTimestamp":1784632803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月16日，Baheal Pharma Group Co., Ltd.增持华昊中天医药-B(02563)2500万股，每股作价4港元，总金额为1亿港元。增持后最新持股数目为2917.08万股，持股比例为7.49%。本交易涉及其他关联方：Baheal Wellness Industry International Trading Limited、Qingdao Baheal Medical Inc.、付钢、北京百洋汇康科技创新发展有限公司、北京百洋同兴管理咨询有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","159938","02563","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175733580","title":"华昊中天医药-B发行25,000,000股新股，已发行股本增至389,588,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175733580","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175733580?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:32","pubTimestamp":1784194343,"startTime":"0","endTime":"0","summary":"北京华昊中天生物医药股份有限公司于2026年7月16日发布公告，披露了截至2026年7月16日的已发行股本变动情况。本次变动源于公司根据2026年5月6日签署的认购协议，以每股4.00港元的价格发行并配发25,000,000股新股，发行日期为2026年7月16日，上述股份数量占本次发行前已发行股本约6.85706%。发行完成后，公司已发行普通股数量由原先的364,588,000股增至389,588,000股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"华昊中天医药-B发行25,000,000股新股，已发行股本增至389,588,000股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135036034","title":"华昊中天医药-B（02563）完成一般授权下2,500万股新股认购 股本扩至3.90亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135036034","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135036034?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:21","pubTimestamp":1784193708,"startTime":"0","endTime":"0","summary":"2026年7月16日，华昊中天医药-B公告称，公司已根据早前签订的认购协议完成交割，并向认购方按每股4.00港元发行25,000,000股新股份。发行完成后，各主要股东持股情况如下：。公司董事会确认，除股本结构变动外，其余条款按此前公告执行完毕。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410944","title":"华昊中天医药-B(02563.HK)完成发行2500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651410944?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:16","pubTimestamp":1784193395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","02563","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104673689","title":"华昊中天医药-B更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1104673689","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104673689?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:42","pubTimestamp":1783078946,"startTime":"0","endTime":"0","summary":"2026年7月3日，北京华昊中天生物医药股份有限公司（华昊中天医药-B，股票代码：02563）发布2026年6月股份变动月报表。报告期至2026年6月30日，公司确认已符合适用的公众持股量要求。\n根据公告，公司本月底登记的注册股本为人民币364,588,000元，较上月底没有变动。普通股H股数目维持364,588,000股，公司当月未进行任何新增发行、购回、注销或持作库存股份事宜。\n公告中显示，报告期内未发生股票期权、权证或可转债等其他权益工具的发行、行使或注销情况。公司确认严格遵守香港联合交易所有限公司《上市规则》等相关规定。\n本次公告由公司秘书陈奕斌签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152361325","title":"港股异动 | 生物医药股逆市活跃，华昊中天医药-B暴涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152361325","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152361325?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:36","pubTimestamp":1781062600,"startTime":"0","endTime":"0","summary":"6月10日，港股生物医药股逆市活跃，$华昊中天医药-B(02563)$暴涨逾40%，$迈威生物-B(02493)$涨逾23%，$宜明昂科-B(01541)$涨逾8%，$银诺医药-B(02591)$、$泰格医药(03347)$、$科伦博泰生物(06990)$、药明康德跟涨。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","VXUS","XBI","159938","161726","BK1161","BK1574","02563","09939","BK1515","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195992437","title":"华昊中天医药-B拟回购不超过已发行H股总数10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195992437","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195992437?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:31","pubTimestamp":1779978711,"startTime":"0","endTime":"0","summary":"华昊中天医药-B发布公告称，公司董事会已通过决议，拟在股东周年大会上请求授予回购已发行H股的授权，最高规模相当于通过相关决议当日已发行H股总数的10%。截至最后公布的可行日期，华昊中天医药-B已发行H股数量为364,588,000股，如获按此规模全数行使回购授权，最高可回购约36,458,800股H股。董事会表示，公司目前并无即刻回购股份的计划，后续将视市场状况及公司实际情况合理行使本次授权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华昊中天医药-B拟回购不超过已发行H股总数10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638974689","title":"华昊中天医药-B(02563)：优替德隆4项临床研究成果入选2026年美国临床肿瘤学会(ASCO)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638974689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638974689?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:39","pubTimestamp":1779892799,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B 发布公告，公司核心产品优替德隆注射液及优替德隆胶囊的四项最新临床研究数据入选2026年美国临床肿瘤学会年会，进行壁报展示。本次入选的四项研究分别针对UTD2治疗晚期乳腺癌I/II期临床试验、UTD2治疗铂耐药卵巢癌II期临床试验、UTD1治疗HER2阳性晚期乳腺癌II期临床试验以及UTD1治疗去势抵抗性前列腺癌II期临床试验。2026 ASCO年会将于2026年5月29日至6月2日在美国芝加哥麦考密克会展中心举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02563","BK1515","09939","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biostar-pharm.com","stockEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":-0.037},{"period":"3month","weight":0.0986},{"period":"6month","weight":0},{"period":"1year","weight":-0.2948},{"period":"ytd","weight":-0.2025}],"compareEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.0858},{"period":"3month","weight":-0.0813},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.1104},{"period":"ytd","weight":-0.1052}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京华昊中天生物医药股份有限公司是一家主要从事创新药研发、生产及销售的中国公司。该公司的产品及管线主要包括优替德隆注射液、优替德隆胶囊、优替德隆纳米剂型、优替德隆抗体偶联药物（ADC）、BG22、BG18和BG44。该公司的产品主要用于治疗复发或转移性乳腺癌、人类表皮生长因子受体2（HER2）阴性乳腺癌新辅助治疗、晚期非小细胞肺癌（NSCLC）、实体瘤、乳腺癌脑转移、肺癌脑转移等脑部肿瘤适应症。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"华昊中天医药-B","nameEN":"BIOSTAR PHARM-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华昊中天医药-B(02563)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华昊中天医药-B(02563)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华昊中天医药-B,02563,华昊中天医药-B股票,华昊中天医药-B股票老虎,华昊中天医药-B股票老虎国际,华昊中天医药-B行情,华昊中天医药-B股票行情,华昊中天医药-B股价,华昊中天医药-B股市,华昊中天医药-B股票价格,华昊中天医药-B股票交易,华昊中天医药-B股票购买,华昊中天医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华昊中天医药-B(02563)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华昊中天医药-B(02563)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}